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Background: Host cell proteins, including cellular kinases, are embarked into intact HIV-1 particles. We have
previously shown that the Cα catalytic subunit of cAMP-dependent protein kinase is packaged within HIV-1
virions as an enzymatically active form able to phosphorylate a synthetic substrate in vitro (Cartier et al. J. Biol.
Chem. 278:35211 (2003)). The present study was conceived to investigate the contribution of HIV-1-associated
PKA to the retroviral life cycle.
Results: NL4.3 viruses were produced from cells cultured in the presence of PKA inhibitors H89 (H89-NL4.3) or
Myr-PKI (PKI-NL4.3) and analyzed for viral replication. Despite being mature and normally assembled, and
containing expected levels of genomic RNA and RT enzymatic activity, such viruses showed poor infectivity.
Indeed, infection generated reduced amounts of strong-strop minus strand DNA, while incoming RNA levels in
target cells were unaffected. Decreased cDNA synthesis was also evidenced in intact H89-NL4.3 and PKI-NL4.3
cell free particles using endogenous reverse transcription (ERT) experiments. Moreover, similar defects were
reproduced when wild type NL4.3 particles preincubated with PKA inhibitors were subjected to ERT reactions.
Conclusions: Altogether, our results indicate that HIV-1-associated PKA is required for early reverse transcription
of the retroviral genome both in cell free intact viruses and in target cells. Accordingly, virus-associated PKA
behaves as a cofactor of an intraviral process required for optimal reverse transcription and for early post-entry
events.
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Reverse transcription is a key step in early replication of
the human immunodeficiency virus type 1 (HIV-1) (for re-
view see [1]). Once entered in the cell cytoplasm, the
single-stranded retroviral RNA genome is converted into a
double-stranded DNA molecule capable to integrate into
the host genome. The reverse transcription is primed by a
human tRNALys3 primer packaged in virions that anneals
to the primer binding site (PBS) and to an 8 nucleotide
base-paired sequence upstream of the PBS known as the
primer activation signal. The elongation reaction is cata-
lyzed by the viral reverse transcriptase (RT), a heterodi-
meric enzyme formed of the p66 subunit that displays
RNA-dependent DNA polymerase and RNase H activities,
associated with the p51 subunit devoid of enzymatic* Correspondence: laurence.briant@cpbs.cnrs.fr
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reproduction in any medium, provided the oractivity. The minus-strand DNA is first synthesized by
copying a short sequence at the 5′ end of the RNA genome
complementary to the R and U5 regions. This step gives
rise to the minus-strand strong stop DNA ((−)ssDNA)).
Concomitantly with the elongation reaction catalyzed by
the RT, the genomic RNA is degraded by RNase H activity
of RT. Then the template is transferred to the 3′ end of
the genome in a reaction facilitated by annealing of the
complementary R regions. This strand transfer allows the
regeneration of the long terminal repeat sequences. Syn-
thesis of the plus-strand DNA ((+)ssDNA) is initiated from
the PPT fragment of genomic RNA and is extended by RT
using a template consisting of (−)ssDNA. The final full
length double-stranded (FL) DNA is generated after a sec-
ond template switch with each strand using other as a
template.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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1 encoded proteins present in the reverse transcription
complex (RTC). Among them, the nucleocapsid protein
(NC) is required for the initiation, chaperoning strand
transfer and spatio-temporal control of the reaction
[2,3]. Expression of Tat and physical contacts of RT with
integrase and Vpr are also required for efficiency initi-
ation of cDNA synthesis [4-6]. Finally, Nef and Vif pro-
teins enhance RT affinity for the RNA genome and allow
temporal regulation of RNA dimerization during early
RT reaction [7-10]. In spite of the amount of informa-
tion available on the mechanisms of HIV-1 DNA synthe-
sis, many of the post-entry events that regulate the
reverse transcription of HIV-1 genomic RNA remain un-
solved (reviewed in [11]). As an example, the exact place
where RT occurs in the infected cell cytoplasm, as well
as the context in which proviral DNA is produced re-
mains unknown. Ex vivo endogenous reverse transcrip-
tion assays (ERT) helped clarifying some aspects of the
reverse transcription process. First, this experimental ap-
proach pointed that the RT reaction is initiated and can
proceed in the intact viral particle [12]. Indeed, (−)ssDNA,
first-strand transfer and full-length minus strand products
are detected in intact core fractions following incubation of
the viral particle with deoxynucleotides (dNTPs). Hence,
the biochemical activities necessary for the completion of
early HIV-1 plus strand synthesis to the second-strand
transfer step are retained in the core particle. Second, a
direct correlation exists between HIV-1 capsid core
organization and reverse transcription. This concept is
supported by the critical morphological modifications
of the retroviral core, including dissolution of the p24-
shelled viral core and absence of the core-envelope linkage
region, observed following intravirion reverse transcription
[13]. Moreover, recent quantification of RT DNA interme-
diates produced in assembled HIV-1 particles revealed that
ERT activity is increased in viral particles incubated with
mild concentration of detergent [14]. Disruption of the
HIV-1 core, by mean of high concentrations of detergents
was, in contrast, coincident with the loss of the ERT activity
of virions, particularly with a significant reduction of late
reverse transcription products synthesis [14]. This aspect is
reminiscent of the inability of p24 mutants with alteration
in core stability to perform reverse transcription [15]. The
persistence of an assembled core structure may therefore
benefit to the reverse transcription process. Third, it is also
clear that reverse transcription most likely involves host cell
cofactors. The significant enhancement of first-strand
transfer and late RT products synthesis evidenced in ERT
assay performed in the presence of cell extracts supports
the contribution of cell encoded proteins in assisting the re-
verse transcription reaction [14,16]. Some of the cofactors
required for proviral DNA synthesis are recruited to the re-
verse transcription complex (RTC) independently ofinteractions with HIV-1 RT. This is illustrated by the cap-
acity of the survival motor neuron (SMN)-interacting pro-
tein 2 (Gemin2), an HIV-1-integrase binding protein, to
enhance the assembly of RT on viral RNA in vitro and to
stimulate (−)ssDNA production in vivo [17,18]. A similar
contribution was also reported for integrase interactor 1
(INI1, hSNF5) [19,20], sin3A-associated protein (SAP18)
and histone deacetylase 1 (HDAC1) [21]. Recruitment to
the RTC of the human topoisomerase Topo1 and of the
DHX9 RNA helicase packaged into HIV-1 particles
through interaction with NC and Gag respectively, is also
required for optimal reverse transcription reaction [22,23].
Recently, two subunits of the eukaryotic elongation factor
1, eEF1A and eEF1G interacting with p51 RT subunit and
the retroviral integrase were reported to assist completion
of reverse transcription by stabilizing the RTC in the cyto-
plasm of the infected cells [24]. A number of cofactors
assisting early steps of HIV-1 replication were also identi-
fied by recent genomic screens [25-27]. Among them, RNA
helicase and DNA repair activities were shown to physically
interact with RT and to assist early post entry steps. Some
of these studies, together with two-hybrid experiments, also
pointed the requirement for A-kinase anchoring protein
(AKAP) proteins, a family of proteins ensuring localization
of the cAMP-dependent protein kinase to cellular mem-
branes, to assist early HIV-1 DNA synthesis. Indeed, both
AKAP13 knock down and inhibition of AKAP149/RNase
H domain of RT interaction were reported to be deleterious
for optimal reverse transcription [25,28]. The exact role of
AKAPs in reverse transcription still remains unelucidated.
Of note, in addition to RT cellular cofactors, host proteins
counteracting HIV-1 reverse transcription have also been
identified in the cell cytoplasm. The category of proteins is
mainly represented by APOBEC3G. This cytidine deami-
nase both generates hypermutation of the newly synthe-
sized (−) strand DNA [29-31] and interferes with RT
displacement along the template by a cytidine-deaminase
independent mechanism [32,33].
Here, we show that the catalytic subunit of the cAMP-
dependent protein kinase (PKA) packaged into HIV-1 viral
particles acts as a cofactor for reverse transcription. Our
previous observations have established that the Cα catalytic
subunit of PKA packaged into viruses is required for viral
infectivity [34]. The present study demonstrates that HIV-1
particles with reduced virus-associated PKA activity, display
mature protein profile and have no apparent alteration in
morphology. They contain wild type genomic RNA levels
and reverse transcriptase activity, but are severely impaired
for synthesis of (−)ssDNA and production of subsequent
RT intermediates in infected cells. Using endogenous re-
verse transcription (ERT) experiments, we provide evidence
that PKA is required for optimal RT reaction in cell free
particles. These results provide new insight into the mecha-
nisms of HIV-1 reverse transcription.
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Phenotypic characterization of HIV-1 particles produced
from PKA-deficient cells
The catalytic subunit of PKA is packaged into HIV-1 parti-
cles. We have previously demonstrated that cultivation of
HIV-1 infected cells with H89, a chemical competitive in-
hibitor of ATP that blocks PKA activity, leads to the pro-
duction of particles containing reduced virus-associated
PKA activity and display poorly infectivity [34]. The present
study was designed to extend these observations and to in-
vestigate the contribution of virus-associated PKA in HIV-
1 life cycle. The number of encapsidated kinases identified
so far in purified HIV-1 particles is limited, and PKA ap-
pears to be the unique packaged host-cell kinase susceptible
to H89 inhibition (for review see [35]). Nevertheless, since
kinase inhibitors generally display large inhibition spectra,
we reconsidered our strategy and used genetic approaches,
siRNA transfection and expression of dominant negative
mutants, to extinguish PKA expression in HIV-1 producing
cells. However, both approaches resulted only in partial in-
hibition of PKA in the HIV-1 producing cell (Additional file
1: Figure S1). According to this reproducible result, we ra-
ther conceived a strategy based on the use of Myr-PKI, a
highly specific cell permeable peptide corresponding to the
active domain of an endogenous PKA inhibitor [36]. HIV-1
particles were produced by transfection of the pNL4.3
molecular clone in 293T cells cultured in the presence of
Myr-PKI using experimental procedures described else-
where [34]. Similar experiments performed in the presence
of H89 inhibitor were run in parallel. Concentrations of
inhibitors used in these experiments were controlled to re-
duce significantly the cAMP-stimulated PKA activity in the
producing cells using an in vitro kinase assay (Additional
file 2: Figure S2A). Viral particles released from these
cells were next subjected to sucrose cushion ultracentri-
fugation and normalized according to p24 content. In
agreement with our previous observations [34], lysate
of NL4.3 particles produced in absence of inhibitor effi-
ciently phosphorylated a PKA peptide-substrate in in vitro
kinase experiments (Additional file 2: Figure S2B). Addition
of 20 μM cAMP to the reaction was unable to enhance
substrate phosphorylation, confirming that HIV-1-
associated PKA is incorporated into HIV-1 particles in
an active form as previously reported [34]. In similar
experimental conditions, normalized amounts of lysed
viruses produced in the presence of Myr-PKI or H89
inhibitors, referred below as PKI-NL4.3 and H89-NL4.3
respectively, displayed reduced virus-associated PKA ac-
tivity (Additional file 2: Figure S2B). Next, infectivity of
virus preparations was tested using the MAGIC-5B indica-
tor cell line expressing a β-galactosidase reporter gene
under the control of HIV-1 LTR [37]. Infection levels were
monitored by quantification of β-galactosidase activity in
whole cell extracts. As presented in Figure 1A, infection ofcells exposed to PKI-NL4.3 and H89-NL4.3 was approxi-
mately 8–10 times lower that observed from cells exposed
to equivalent amounts of wild-type NL4.3 particles. The
cAMP/PKA pathway is recognized to control HIV-1 tran-
scriptional activity through TPA responsive elements
(TRE)-like cAMP-responsive elements within the 5′-
untranslated (U5) leader [38]. Inhibition of cellular PKA ac-
tivity could therefore decrease LTR-driven transcriptional
activity in MAGIC-5B cells. Accordingly, we evaluated the
possible interference of any contaminating PKA inhibitor
that would have co-sedimented with viral preparation.
Mock-transfected cells were maintained in the presence of
H89 or Myr-PKI inhibitors in conditions identical to those
used for virus production. Then, supernatants were sub-
jected to sucrose cushion ultracentrifugation, pellets were
resuspended and mixed with NL4.3 viruses produced from
PKA proficient cells. Ratio of inhibitor-containing super-
natants to NL4.3 particles was chosen to mimic viral
preparations used in Figure 1A. Then the mixtures were
incubated with MAGIC-5B cells. As shown in Figure 1B,
no significant difference in HIV-1-induced LTR-driven
β-galactosidase reporter gene expression was observed
for NL4.3 and viral preparations supplemented with
Myr-PKI- or H89-containing supernatants. Accordingly,
reduced infectivity observed for H89-NL4.3 and PKI-
NL4.3 preparations in Figure 1A could reasonably not
be ascribed to contamination of viral preparation with
cosedimented inhibitor.
H89-NL4.3 and PKI-NL4.3 display distinct phenotypes in
primary human CD4+ lymphocytes and macrophages
Next, we tested whether viral phenotypes observed
using the MAGIC-5B indicator cell line were conserved
in primary human cells. PBMCs were prepared from
blood samples from uninfected donor and CD4+ lym-
phocytes or macrophages were isolated using magnetic
beads-conjugated mAbs directed to cell surface antigens
and magnetic field separation. After activation, cells
were infected with normalized amounts of NL4.3, H89-
NL4.3 or PKI-NL4.3. As attested by qPCR analysis,
HIV-1 DNA levels were significantly reduced in PBMCs
infected with H89-NL4.3 and PKI-NL4.3 as compared
with copy number detected in cells infected with
NL4.3 (Figure 2). A similar tendency was observed
when CD4+ primary lymphocytes were processed in
similar condition. Altogether, these data corroborate
our previous observations [34] and indicate that NL4.3
viruses produced from cells with poor PKA activity are
impaired for infectivity. To evaluate the role of HIV-1-
associated PKA in primary macrophages, CCR5-tropic
NL81.A HIV-1 viruses were produced by transfection
of HEK 293T cells cultured in the presence PKA inhibi-
tors using above described experimental procedures.















































Figure 1 Infectivity of H89-NL4.3 and PKI-NL4.3. (A) Infectivity of normalized amounts of sucrose purified NL4.3, PKI-NL4.3 and H89-NL4.3
(10 ng p24 standardized to a final volume of 100 μL) was assayed in MAGIC-5B indicator cell lines. Control experiments consisted of mock
infected cells (−) or NL4.3 infected cells maintained in the presence of 10 μM AZT. Infectivity was quantified by β-galactosidase activity in total cell
lysate. Each value represents an average of three experiments performed in triplicate ± standard deviation. (B) Evaluation of viral samples
contamination by co-purifying inhibitors. Supernatant (Sup.) of uninfected 293 cells maintained in medium alone (Mock) or cultured in the
presence of H89 or Myr-PKI were subjected to gradient sucrose ultracentrifugation. Samples (100 μL) were then mixed with NL4.3 viruses
(10 ng p24) produced from PKA proficient cells and the mixture was used to infect MAGIC-5B cells. Infectivity was measured as described in (A).
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comparable retroviral cDNA levels. Altogether, these data
indicate that HIV-1 produced from PKA-deficient cells
display similar phenotypes in MAGIC-5B indicator cells
























Figure 2 Phenotypes of HIV-1 lacking PKA activity in primary
human cells. Infectivity of normalized amounts of sucrose purified
NL4.3, PKI-NL4.3 and H89-NL4.3 (50 ng p24 standardized for 1x106 cells)
was assayed in PBMCs, CD4+ lymphocytes. Similar experiments were
performed using primary monocyte-derived macrophages as target
cells and NL81.A, PKI-NL81.A and H89-NL81.A viruses. At day 6
post-infection, HIV-1 DNA levels were monitored by qPCR amplification.
Control experiments consisted of mock infected cells (−) or NL4.3- or
NL81.A-infected cells maintained in the presence of 10 μM AZT. Data
represent the average of duplicates ± SD and are expressed as
percentages of wild-type conditions.reduced viral replication in these cells were apparently
efficiently compensated in macrophages since H89-
NL81.A and PKI-NL81.A replicated at wild type levels
in these cells.
H89-NL4.3 and PKI-NL4.3 viruses are fully mature and
normally assembled
In an attempt to investigate the nature of defects account-
ing for reduced infectivity of H89-NL4.3 and PKI-NL4.3
viruses, viral particles were next analyzed for protein con-
tent, maturation and assembly. Cell free particles or total
extracts prepared from the corresponding producing cells
were lysed and subjected to immunoblotting analysis. Sam-
ples were normalized according to total protein content for
cell extracts and depending on the p24 concentration for
viral particles preparations. Similar HIV-1 protein patterns
were observed in cells cultured in absence or presence of
PKA inhibitors. Regarding cell free particles, mature p24
was detected at similar levels in NL4.3, PKI-NL4.3 or H89-
NL4.3 particles. Also, levels of mature RT subunits and
gp41 incorporation were similar in all viral samples ana-
lyzed (Figure 3A). Real time reverse transcription PCR
(qRT-PCR) analysis revealed that genomic RNA was pack-
aged with similar efficiency in NL4.3, PKI-NL4.3 and H89-
NL4.3 viruses (Figure 3B). Finally, electron microscopy
imaging of individual particles revealed no visible difference
in morphology, size or maturation between these viruses
(Figure 3C and 3D). Accordingly, infectivity defects ob-
served for NL4.3 viruses produced in the presence of Myr-
PKI or H89 could be inferred neither to alteration of viral
proteins incorporation or maturation, nor to impaired nu-





































































Figure 3 Characterization of PKI-NL4.3 and H89-NL4.3 viral particles. (A) 293T cells expressing HIV-1 NL4.3 were maintained in the presence
of medium alone or supplemented with Myr-PKI (PKI) or H89 inhibitors. Normalized amounts of cells lysates (left panel) or sucrose cushion
purified viruses (right panel) were sequentially probed with rabbit anti-RT or anti-gp41 sera or anti-p24 mAbs. (B) Genomic RNA in viral particles
was quantified by qRT-PCR. Values are expressed as percentages of NL4.3 values ± SD. (C) NL4.3, PKI-NL4.3 and H89-NL4.3 viral particles were
imaged by electron microscopy. Bar = 100 nm. (D) The number of fully mature and aberrant viruses was counted in each sample and expressed
as a percentage of total observation (NL4.3 n = 57; PKI-NL4.3 n = 105; H89-NL4.3 n = 18). Error bars represent 95% confidence intervals.
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reverse transcription
Life cycle of H89-NL4.3 or PKI-NL4.3 viruses was next
addressed by monitoring incoming genomic RNA in in-
fected cells and quantifying cDNA intermediates synthe-
sized during reverse transcription. First, levels of genomic
RNA present in MAGIC-5B cells were quantified by qRT-
PCR. Samples were prepared 1 hour after viral exposure
to avoid sample contamination with de novo synthesized
viral mRNAs and infections were performed in the pres-
ence of 10 μM AZT in order to prevent degradation of the
RNA genome by the RT RNAse H activity during progres-
sion of the reverse transcription reaction. Similar RNA
copy numbers were detected in cells infected with WT,
H89-NL4.3 or PKI-NL4.3 viruses (Figure 4A). Preincuba-
tion of the cells with the T20 fusion inhibitor significantly
reduced genomic RNA levels detected in the cells follow-
ing infection with any virus tested, attesting for the specifi-
city of our data. Because all viruses could enter target cells
equally well, the rate and extent of reverse transcription
performed by these viruses were analyzed by qPCR ampli-
fication of DNA intermediates 24 hours post-infection. In
these experiments, viruses were treated with DNAse-Ibefore addition to MAGIC-5B cells to remove any contam-
inant plasmid DNA in viral preparations. As shown in
Figure 4B, the amount of (−)ssDNA detected in cells in-
fected with H89-NL4.3 or PKI-NL4.3 was 5 to 15% that
quantified in cells infected with NL4.3. A similar reduction
was observed when the late RT product, second strand
transfer DNA, was amplified. As expected, control consist-
ing of cells infected with NL4.3 maintained in the presence
of 10 μM AZT immediately after virus challenge showed
reduced levels of both early and late reverse transcription
intermediates. Altogether these data indicate that H89-
NL4.3 and PKI-NL4.3 viruses efficiently infect their target
cells, but are impaired for early reverse transcription.
H89-NL4.3 and PKI-NL4.3 viruses display wild type
intrinsic reverse transcriptase activity
DNA synthesis defects evidenced for H89-NL4.3 and PKI-
NL4.3 viruses reflect an impairment of the reverse tran-
scription reaction. Therefore, we analyzed the enzymatic
activity of reverse transcriptase packaged in H89-NL4.3
and PKI-NL4.3. Viral particles were lysed in the presence
of NP-40 and incubated with a mixture of exogenous
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Figure 4 Quantification of genomic RNA and reverse transcription intermediates in cells infected with NL4.3, PKI-NL4.3 or H89-NL4.3
viruses. MAGIC-5B cells were infected with normalized amounts of NL4.3, PKI-NL4.3 or H89-NL4.3. Levels of genomic RNA (A) or (−)ssDNA or
second strand transfer cDNA (B) in the infected cells were monitored by qRT-PCR or qPCR respectively. Control experiments consisted of mock
infected cells (−) or NL4.3 infected cells maintained in the presence of 10 μM AZT. Values are expressed as percentage of NL4.3 conditions ± SD.
Specificity of qRT-PCR detection of genomic RNA was controlled by preincubation of the cells for 30 min at 37°C in the presence of 1 μg/ml T20
fusion inhibitor before virus exposure.
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of dNTP incorporated into the template, was identical for
normalized amounts of the three viruses (Figure 5A). To
analyze further whether virus-associated PKA activity was
required for activity of the reverse transcriptase, we re-
peated RT assays using lysate of NL4.3 viruses supple-























Figure 5 Quantification of intrinsic RT activity contained in NL4.3, H8
sucrose-purified NL4.3, PKI-NL4.3 or H89-NL4.3 viruses were lysed and subjected
template/primer hybrid and dNTPs. (B) RT reactions were performed with lysate
(50 μM) inhibitors. Addition of nevirapine (Nev) to the reaction mixture was use
the Material and Methods section. Results are the mean of three separate experH89. As shown in Figure 5B, RT-catalyzed cDNA synthesis
from a synthetic template/primer was identical in presence
or in absence of inhibitor. As expected, nevirapine, an
inhibitor of RT, used in the same conditions almost com-
pletely inhibited the exogenous RT reaction. Accordingly,
enzymatic activity of the HIV-1 reverse transcriptase does





















9-NL4.3 and PKI-NL4.3 particles. (A) Normalized amounts of
to RT reaction in the presence of exogenous poly(A)/oligo dT
of NL4.3 viruses incubated in the presence of H89 (100 μM) or Myr-PKI
d as a negative control. RT activity was quantified by ELISA as described in
iments performed in triplicate ± standard deviation.
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PKA inhibitors
Reverse transcription can be initiated by addition of dNTPs
into intact or mildly permeabilized HIV-1 particles, leading
to the synthesis of FL DNA [12,16]. This experiment,
referred to ERT (endogenous reverse transcription) assay
merely serves as a model for understanding the reverse
transcription occurring inside target cells. When per-
formed using intact viral particles or virions incubated with
low detergent concentrations, it gives access to the ability
of the machinery contained in virions to produce proviral
DNA using the RNA genome as a template and the
tRNALys3 primer [14]. To decipher with the RT defect ob-
served for PKI-NL4.3 and H89-NL4.3 viruses, viral parti-
cles were subjected to ERT reactions. Sucrose purified
particles were permeabilized by addition of 0.1 mM Triton

















































































Figure 6 Synthesis of (−)ssDNA in permeabilized NL4.3, H89-NL4.3 an
with 0.1 mM Triton X-100 were subjected to ERT reactions run for 16 h in t
incubation of viruses with dNTPs and 20 μg/mL nevirapine (Nev). (−)ssDNA
expressed as absolute copy numbers. Error bars indicate standard deviation
reactions as described in (A). (C) and (D) Accessibility of ERT products synth
addition 4 U DNase and 105 copies of a tracer plasmid to the reaction mixture
tracer plasmid copy numbers were determined by qPCR. Values are expressedcDNA. Addition of low Triton X-100 concentrations (up
to 0.1 mM) to the reaction mixture was reported to en-
hance levels of proviral DNA by permeabilizing the virion
to nucleotides without destabilizing the viral particle [14].
Then, the reaction products were extracted and quantified
by qPCR. Using these conditions, (−)ssDNA was detected
at very low levels in NL4.3 particles maintained in absence
of dNTPs and was drastically enhanced by addition of
dNTPs (Figure 6A). Synthesis was abolished by addition of
the membrane permeable inhibitor of reverse transcriptase
nevirapine to the mixture, attesting for the specificity of
the reaction. Next, PKI-NL4.3 and H89-NL4.3 viruses
were subjected to ERT reactions using similar experimen-
tal conditions. When compared with NL4.3 viruses, (−)
ssDNA synthesis was reduced by 44% and 27% for PKI-
NL4.3 and H89-NL4.3 particles respectively (Figure 6B).













































d PKI-NL4.3 viruses. (A) Sucrose purified NL4.3 viruses permeabilized
he presence or absence of dNTPs. Control experiments consisted of
copy numbers were determined in each sample by qPCR. Values are
s (n = 4). (B) PKI-NL4.3 or H89-NL4.3 particles were subjected to ERT
esized in NL4.3, H89-NL4.3 and PKI-NL4.3 particles was monitored by
. After DNase inactivation and nucleic acids extraction, (−)ssDNA and
as a percentage of DNA levels detected in no DNAse reactions.






































Figure 7 Contribution of virus-associated PKA activity in
endogenous reverse transcription. NL4.3 viruses were subjected
to ERT experiments run in the presence of dNTPs and increasing
concentrations of H89 (A) or Myr-PKI (B). For each reaction, nucleic
acids were extracted and (−)ssDBNA production was quantified by
qPCR amplification. DNA levels detected in ERT reactions performed
in the presence of nevirapine are indicated by a dotted line. Data
are mean values of duplicate experiments and are expressed as a
percentage of WT conditions.
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ERT reaction. To examine whether such defects were
linked to modification of the integrity of viruses engaged in
the reaction, ERT experiments were repeated and followed
by a DNAse digestion step of the final reaction mixture. A
tracer plasmid (105 copies) was added to the mix to control
the efficiency of DNAse treatment. Then, total DNA
present in the reaction was extracted and both proviral
DNA synthesized in viral particles and tracer plasmid were
monitored by qPCR. In our experimental conditions, levels
of tracer plasmid detected by qPCR were reduced to back-
ground level by DNAse treatment, attesting for the effi-
ciency of the digestion step (Figure 6C). In contrast, (−)
ssDNA detected in NL4.3 particles following addition of
dNTPs were only reduced by 40%, indicating that HIV-1
cDNA remained mostly inaccessible to degradation by
DNAse. Accordingly, as previously demonstrated by others
Triton X-100 used at a 0.1 mM concentration perme-
abilized the virions to nucleotides without totally disrupt-
ing the viral particles and allowed intraviral genome
reverse transcription [14]. When applied to ERT products
generated by Triton-permeabilized H89-NL4.3 or PKI-
NL4.3 particles, DNAse I treatment reduced levels of (−)
ssDNA and tracer plasmid in proportion similar to that
observed for NL4.3 particles (Figure 6D). Therefore, the
reduced capacity of H89-NL4.3 and PKI-NL4.3 viruses to
produce (−)ssDNA in ERT experiments cannot be ascribed
to drastic structural modification of the viral particles. Fi-
nally, to investigate whether the reduced efficiency of ERT
observed in PKI-NL4.3 and H89-NL4.3 viruses was not
due to any defect acquired during particles biogenesis,
NL4.3 particles were subjected to ERT reaction performed
in the presence of PKA inhibitors. The above-described ex-
perimental procedures were repeated starting from Triton
X-100-permeabilized NL4.3 particles incubated in the pres-
ence of dNTPs, but reactions were supplemented with in-
creasing concentrations of Myr-PKI or H89 before allowing
viral DNA synthesis. As shown in Figure 7A and 7B, (−)
ssDNA synthesis decreased as the concentration of H89 or
Myr-PKI increased in the reaction (Figure 7A and 7B). The
addition of 100 μM H89 lowered ERT activity by 25% for
H89 and Myr-PKI decreased (−)ssDNA synthesis by 70%
when added at 50 μM. Accordingly, H89 and Myr-PKI
likely inhibit an intraviral process in NL4.3 particles re-
quired for optimal efficiency of the early reverse transcrip-
tion reaction.
Discussion and conclusion
The aim of this study was to decrypt the role played by
HIV-1-associated PKA in virus infectivity. To this end we
took advantage of our capacity to produce HIV-1 particles
containing reduced PKA activity. This goal was previously
achieved by mean of the cell-permeable H89 inhibitor of
PKA [34]. To improve the specificity of our experimentalmodel, we initially focused on the use of siRNA targeting
mRNA encoding the Cα catalytic subunit of PKA. Unfor-
tunately, despite reducing significantly intracellular PKA
levels, a basal expression remained in the producing cells
that accounted for residual PKA incorporation into vi-
rions. These viral particles were approximately 40% less
infectious than normalized amounts of wild type HIV-1.
Similarly, ectopic expression of a D324G mutant of PKA-
RIα regulatory subunit, that is unable to dissociate from
PKA catalytic subunit, resulted in an intermediate pheno-
type (Additional file 1: Figure S1). Accordingly, this strategy
was abandoned in favour of the use of chemical inhibitors
whose capacity to inhibit PKA rely on distinct mechanisms.
Myr-PKI is a myristoylated peptide which contains a PKA
substrate consensus sequence with the serine phosphor-
acceptor site replaced by alanine [36]. This peptide inhibits
PKA enzymatic activity and displays high selectivity by
docking to the substrate binding site of the kinase [39]. The
parallel use of Myr-PKI with that of H89, a competitive
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the risk to focus on off target effects resulting from wide
spectrum kinase inhibitory properties.
Here we found that HIV-1 particles produced from
virus-expressing cells cultured in the presence of H89 or
Myr-PKI concentration effective at inhibiting cellular PKA
activity were fully mature and displayed no apparent as-
sembly defect. Particularly, they contained expected levels
of mature p51 and p66 RT subunits and intrinsic RT activ-
ity was unaffected as evidenced in exogenous RT assays
performed using a synthetic poly(rA)/oligodT template.
Moreover, genomic RNA content was comparable to that
of wild type NL4.3 particles. H89-NL4.3 ad PKI-NL4.3
viruses efficiently infected targets cells as supported by the
levels of incoming genomic RNA in cell extracts. However,
these viruses displayed reduced infectivity and were unable
to reverse transcribe the viral genome into FL proviral
DNA. Indeed, viruses were defective for (−)ssDNA pro-
duction indicating that an early step of the reverse tran-
scription process was impaired. Testing of intrinsic RT
activity associated with H89-NL4.3 and PKI-NL4.3 viruses
together with experiments based on incubation of wild
type RT in the presence of chemical inhibitors revealed
that reverse transcriptase enzymatic activity was un-
affected by PKA perturbators. Nevertheless, H89-NL4.3
and PKI-NL4.3 viruses displayed a reduced capacity to
produce (−)ssDNA in ERT, when incubated with dNTPs
in conditions maintaining the integrity of viral particles.
Accordingly, such viruses were defective for an intraviral
process required for optimal reverse transcription. Inter-
estingly, ERT could be inhibited in NL4.3 particles by
addition of PKA inhibitors to the reaction mixture. There-
fore, the possibility that the decreased DNA synthesis evi-
denced for H89-NL4.3 and PKI-NL4.3 viruses in ERT
experiments is consecutive to an interference with intra-
cellular assembly in cell cultured in the presence of PKA
inhibitors can be reasonably rejected. As PKA is incorpo-
rated in an active form in HIV-1 particles [34], our data
support that the virus-associated kinase is required either
to produce a functional reverse transcription complex in
the viral particle or to create the appropriate microenvir-
onment required for optimal reverse transcription.
The exact contribution of PKA in proviral DNA syn-
thesis needs further investigation. A number of studies
have indicated that p51 and p66 subunits of HIV-1 re-
verse transcriptase are post-translationally modified in
virions, infected cells and RTCs [40,41]. Such modifica-
tions enhanced reverse transcription efficiency and
progression. However, the contribution of PKA in RT
phosphorylation was rejected [42]. Nevertheless, it re-
mains possible that virus-associated PKA could modify
a virus-incorporated HIV-1 encoded protein assisting
reverse transcription. In this context, the role of Nef
and Vpr, two PKA-phosphorylated proteins bothknown to be required for proviral DNA synthesis, needs to
be investigated [43,44]. A possible regulation of RT through
modulation of the APOBEC3G/Vif interplay should also be
considered as PKA-mediated phosphorylation of APO-
BEC3G can regulate the interaction between A3G and Vif
[45]. In addition, the capacity of PKA to phosphorylate the
HIV-1 p24 protein in vitro and to interact with PKA in vivo
has to be kept in mind [34]. Indeed, substitution mimicking
phosphorylation of serine residues identified as phospho-
acceptor sites either in the p24 interdomain linker or in
helix 9, a dimerization interface required for core assembly,
inhibits reverse transcription [46]. Such mutations rendered
the HIV-1 core unstable and generated mild assembly de-
fects. According to these data, and to data presented herein,
HIV-1-associated PKA could fulfill a complex role during
post-entry steps of HIV-1 infection through the phosphor-
ylation of multiple targets thereby creating a microenviron-
ment that favours the initiation and the progression of the
reverse transcription. A series of experiments is under
progress to test these hypotheses.
Finally, phenotypes observed for H89-NL4.3 and PKI-
NL4.3 viruses differed according to the target cell. RT
defects observed in indicator cells and CD4+ lymphocytes
were efficiently compensated in macrophages, allowing syn-
thesis of wild type levels of proviral DNA. Suppressing host
cell cAMP-dependent PKA activation by β-chemokines
(MIP-1α, MIP1-β and RANTES) was previously reported
to inhibit HIV-1 cDNA synthesis in primary CD4+ lympho-
cytes but not in macrophages [47]. In agreement with these
observations, our data indicate that HIV-1-associated PKA
might exert differential effects in primary lymphocytes and
macrophages and that post-entry steps may significantly
differ in these two cell types.
Overall, a complex interplay between PKA and HIV-1 in-
fection has been reported in the literature. Increased intra-
cellular levels of cAMP and constitutive activation of PKA
were measured in cells from HIV-1 infected patients [48].
Such defect correlated with T cells dysfunction and
immunodeficiency [48-50]. To the opposite, reduction of
intracellular cAMP levels or PKA agonists restores immune
responses in T cells isolated from HIV-1 infected patients
through the inhibition of the cAMP/PKA pathway [48,51].
At the cell level, modulation of the cAMP/PKA pathway
was reported to enhance HIV-1 replication at multiple
steps, including LTR-driven HIV genes transcription
[47,52,53] and proviral DNA synthesis [47,52,53]. Here, we
showed that incorporation of an active PKA determines the
efficiency of early steps of reverse transcription in a new
target cell. In light of these observations, both the PKA-
dependent pathway in the target cell and virus-associated
PKA represent key players in HIV-1 replication and patho-
genesis. This model agrees with the results of recent meta-
analysis of genome-wide studies that identified PKA as an
important host factor in early HIV-1 replication [26].
Giroud et al. Retrovirology 2013, 10:157 Page 10 of 13
http://www.retrovirology.com/content/10/1/157Methods
Cells
Human embryonic kidney 293T cells and the MAGI-5B
indicator cell line [37] were cultured in Dulbecco’s modi-
fied Eagle’s medium (Life Technologies, Inc.) supplemented
with 10% fetal calf serum (Cambrex), 100 units/mL penicil-
lin, 100 μg/mL streptomycin. Peripheral blood mono-
nuclear cells (PBMCs) from healthy donors were isolated
from buffy coats by Ficoll-Hypaque gradient centrifugation.
CD14+ monocytes were isolated with anti-human CD14-
coated magnetic beads (Miltenyi Biotec) according to
manufacturer recommendations and differentiated into
macrophages by incubation for 5 days in complete medium
(RPMI 1640-10% fetal calf serum) supplemented with
hM-CSF (Immunotools). CD4+ T cells were isolated from
CD14 − peripheral blood lymphocytes with a CD4+ T-cell
enrichment kit (Stem Cell Technologies). Cells were then
resuspended in RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum and stimulated for
3 days with 5 μg/ml phytohemagglutinin in the presence of
20 U/ml of interleukin-2 (Roche).
Viral stock production
Viral stocks were generated as previously described
[34]. 293T cells (5x106) were transfected with 30 μg of
pNL81.A (kindly provided by W.C. Greene) or pNL4.3
DNA (AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH) using calcium phos-
phate precipitation. Twenty-four hours post transfec-
tion, the cells were extensively washed and cultured for
an additional 16 h in medium alone or supplemented
with 100 μM H89 (Sigma-Aldrich) or with 50 μM
Myr-PKI peptide (Myr-14GRTGRRNAI22-NH2) (Sigma-
Aldrich). Virus-containing supernatants were collected,
filtered onto 0.45 μm membranes. All viral preparations
were purified by centrifugation through 20% sucrose
cushion at 25,000 rpm for 2.5 h at 4°C in a Sw32Ti rotor
(Beckman Coulter, France). The pellets were resus-
pended in PBS, aliquoted and stored at −80°C. Viral
stocks were normalized according to p24 content using
an anti-p24 Enzyme-linked Immunosorbent Assay
(Ingen, France).
Viral infectivity assays
MAGI-5B cells which stably express the β-galactosidase
reporter gene cloned downstream of the HIV-1 LTR pro-
moter were platted at 8 × 103 cells/100 μL in 96 wells
plates. The cells were exposed to viral solutions normal-
ized according to p24 content. 48 hours post-infection,
virus infectivity was monitored by measurement of β-
galactosidase activity from the cell lysates as previously
described using the Galactostar β-galactosidase assay kit
(Applied Biosystem). Luminescence was recorded using a
Centro XS3 LB960 luminometer (Berthold, France). Valueswere normalized according to protein content of the cell
extract (BCA assay kit, Pierce). T20 fusion inhibitor was
obtained from the AIDS Research and Reference Reagent
Program (Division of AIDS, NIAID, NIH).
Immunoblotting analysis
Cell or sucrose-purified virions were solubilized in RIPA
buffer and separated on a 12.5% SDS-PAGE. Proteins were
transferred to PVDF membrane (Millipore) and revealed
using a rabbit polyclonal serum directed to RT (kindly pro-
vided by J. L. Darlix, ENS, Lyon, France) or mAbs raised
against CA (Biogenesis) or anti-gp41 (Fitzgerald Inc.). Sec-
ondary antibodies conjugated to horseradish peroxidase
were revealed by enhanced chemiluminescent detection
(Pierce Biotechnology Inc.).
Electron microscopy analysis
Virus-producing cells were processed for thin-layer electron
microscopy as described elsewhere [34]. Briefly, the cells
were fixed in situ with 2.5% glutaraldehyde in cacodylate
buffer (pH 7.4) for 60 min at 4°C. Cells were then post-
fixed with 2% osmium tetroxide, washed in cacodylate
buffer containing 0.5% tanic acid, and embedded in epon
(Embed-812, Electron Microscopy Sciences Inc.). Prepara-
tions were examined with a Hitachi H.7100 transmission
electron microscope (CRIC, University Montpellier 1,
France).
qPCR analysis of genomic RNA and proviral DNA
Total RNA isolated from cells challenged with HIV for 1 h
or genomic RNA contained in HIV-1 particles (100 ng
p24) was extracted with Tri-Reagent (Sigma, France) and
subjected to qRT-PCR analysis as previously described
[54]. Briefly, a poly(dT) olygonucleotide was used as RT-
primer and subsequent qPCR was performed with a the
SYBR® Green PCR Master Mix (Roche, France) on the
RotorGene system (Labgene, France). A 90 bp fragment in
the R-U5 region from the HIV-1 RNA was amplified using
5′-AGCAGCTGCTTTTTGCCTGTA-3′ and 5′-AAGCA
GTGGGTTCCCTAGTTAG-3′ oligonucleotides. A stand-
ard curve was generated from 102 to 106 copies of pNL4.3
plasmid. Each assay was accompanied by controls without
reverse transcriptase (DNA contamination levels <1% of
HIV-1 RNA). The copy numbers of HIV-1 genomic RNA
in cell samples were normalized to that of the GAPDH
mRNA quantified in parallel as endogenous control.
For proviral DNA analysis, total DNA was extracted
from cells infected for 24 h with DNAse I-treated virus,
using the DNeasy extraction kit (Qiagen). In order to
check for the absence of contaminating plasmid (pNL4.3
or pNL8.1A) in samples, DNA preparation were tested
with a primer pair that specifically amplifies the pUC
region of the molecular clone as previously reported [46],
and all samples found positive were discarded. HIV-1
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elsewhere [46]. Primers used for amplification were: (−)
ssDNA: #73: 5′-ACACAACAGACGGGCACACAC-3′ and
#187: 5′- GGTCTCTCTGGTTAGACCA-3′; second strand
transfer DNA #169: 5′-AGCAGCTGCTTTTTGCCTGT
A-3′ and MA: 5′-CCTGCGTCGAGAGATCTCCTCGG-3′.
Analysis of intrinsic reverse transcriptase activity
Exogenous reverse transcription assays were performed
to measure the enzymatic activity of the RT contained in
lysate of viral particles (3 ng p24) when incubated in the
presence of synthetic poly(rA)-oligo(dT) template and
primer using the Reverse transcriptase assay colorimetric
kit (Roche, France).
Endogenous reverse transcription assays (ERT)
Proviral DNA synthesis in assembled viral particles perme-
abilized with reduced amounts of detergent was deter-
mined in ERT assays. This assay is based on the use of
endogenous RNA genome as a template and that of the en-
dogenous tRNALys3 as a primer. Sucrose cushion-purified
virus particles (normalized according to p24 content to
10 ng) were incubated for 18 h at 37°C in the presence of
0.1 mM Triton X-100, 10 mM Tris, pH 7.4, 10 mMMgCl2,
and 200 μM of each dNTP in a final volume of 50 μL. Nu-
cleic acids were then extracted with DNeasy extraction col-
umns (Qiagen) and eluted in 200 μL of water. RT products
were quantified by qPCR amplification using 2.5 μL as
template. As a control, the same mix was prepared for each
sample but without dNTPs and a no-nucleotide control
reaction mixture was always included. Accessibility of
reverse transcription products to degradation after the
permeabilization of virions with detergent was assayed
by addition of 4U DNase I (Life Technologies) to the
ERT products and incubation for 30 min at 37°C before
nucleic acids extraction.
Ethical approval
Primary human cells used for this work were obtained from
the French blood establishment (EFS, Toulouse, France) in
accordance with international ethical principles and French
national law under declaration N° DC-2008-207 to the
French Ministry of Research and Higher Studies.Additional files
Additional file 1: Figure S1. siRNA against PKA-Cα or expression of
dominant negative RI-α regulatory subunit in the producer cells reduce
infectivity of NL4.3 particles. (A) MAGIC-5B cells were transfected with
50 nM control siRNA (siC) or siRNA against PKA Cα subunit (siPKA) (Cell
Signaling Technology) using Interferin transfection reagent (Polyplus
Transfection). Seventy-two hours after transfection, the culture was
infected with HIV-1 NL4.3 and viral particles released in supernatants
during the next 12 h were collected. Infectivity of virus preparations
(20 or 50 ng p24 standardized to a final volume of 100 μl) was assayedin MAGIC-5B indicator cell lines. Mock infected cells (−) are shown as
control. Each value represents the mean of duplicate experiments ±
standard deviation. (B) Expression of PKA-Cα in virus-producing cells
was monitored over time by immunoblot analysis. Proteins levels
loaded in each line were monitored by incubation with anti-tubulin
mAbs (Santa-Cruz Biotechnology, Inc.). (C) 293 T cells expressing the pNL4.3
HIV-1 molecular clone were transfected with the promoter inducible pPKA
RIαD324G plasmid encoding a dominant negative (DN) regulatory subunit
unable to release PKACα [55] (kindly provided by Pr. B. Schimmer, University
of Toronto) or with an empty vector (Mock) and culture in the presence of
100 μM Zn2+ for 24 h to induce transgene expression. Virions released in
culture supernatant were normalized to 10 ng p24 and used to infect
MAGIC-5B cells. Infectivity was determined by quantification of reporter
gene expression in cell lysates. PKA activity in the producing cells was
determined using the MESACUP protein kinase assay kit (MBL, Ltd., Nagoya,
Japan). Values are expressed as percentage of mock conditions.
Additional file 2: Figure S2. PKA is incorporated in an active form in
NL4.3 but not in PKI-NL4.3 or H89-NL4.3 particles. (A) PKA activity in lysate
of HIV-1-producing 293 T cells cultured in medium alone or in the
presence of H89 or Myr-PKI was determined using the MESACUP protein
kinase assay kit (MBL, Ltd., Nagoya, Japan). Addition of cAMP (20 μM) to
the reaction mixture was used to stimulate kinase activity. (B) Normalized
amounts of purified NL4.3, PKI-NL4.3 and H89-NL4.3 viruses were lysed
and analyzed for PKA activity. NL4.3-associated kinase activity remained
unchanged when 20 μM cAMP was added to the reaction mixture but
was reduced by addition of H89 (20 μM) or Myr-PKI (10 μM) to the
reaction mix, attesting that PKA is incorporated into HIV-1 particles in an
active form. In these experimental conditions, kinase activity associated
with normalized amounts of PKI-NL4.3 or H89-NL4.3 lysates was significantly
reduced as compared with that detected from NL4.3 particles.
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